G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US

March 3, 2021 Auto Bot approval, Boehringer Ingelheim, FDA, First, G1 Therapeutics, Pharma 0

Shots:

  • On Feb 12, 2021, the US FDA has approved Cosela to decrease the incidence of CT induced myelosuppression in adult patients when administered before a platinum/etoposide-containing regimen or topotecan-containing regimen for ES-SCLC
  • The launch is supported by the “One Patient Support Program” which is designed to provide access and affordability solutions to eligible patients
  • Cosela is the 1st therapy designed to help protect bone marrow (myeloprotection) when administered before treatment with CT

Click here ­to­ read full press release/ article | Ref: GlobeNewswire  | Image: BioSpace

The post G1 Therapeutics and Boehringer Ingelheim Launch Cosela (trilaciclib) in the US first appeared on PharmaShots.